Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Report 2025 – Analysis and Outlook

 What is the present valuation and projected CAGR of the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market?

The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market size has grown strongly in recent years. It will grow from $5.69 billion in 2024 to $6.17 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to increased prevalence of underlying conditions, advancements in diagnostic tools, pharmaceutical developments, rising global healthcare access.

The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market size is expected to see strong growth in the next few years. It will grow to $8.32 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to telemedicine and remote monitoring, data analytics and ai, patient education and support, regulatory changes and reimbursement policies. Major trends in the forecast period include personalized treatment approaches, development of novel therapies, minimally invasive diagnostics, collaborative care models.



Get Your Free Sample of The Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Report:
Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Report 2025, Analysis And Outlook Sample

How has the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market evolved, and what factors have shaped its growth?

The increasing number of people with diabetes is expected to propel the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market going forward. Diabetes refers to a chronic metabolic disorder characterized by high blood sugar levels (hyperglycemia) over a prolonged period. This condition results from the body's inability to produce enough insulin or effectively use the insulin it produces. EPI therapy, which involves pancreatic enzyme replacement therapy (PERT), can help improve nutrient absorption in people with diabetes and EPI. It can also help improve glycemic control in people with diabetes. For instance, in June 2024, according to The National Health Service (NHS England), a UK-based publicly funded healthcare system, in 2023, the number of individuals identified by the NHS in England as having pre-diabetes rose to 3,615,330, marking an 18% increase from 3,065,825 in 2022. Additionally, among those under 40, cases surged nearly 25%, growing from 173,166 in 2022 to 216,440 in 2023. Therefore, the increasing number of people with diabetes is driving the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.

What are the major segments of the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market?
The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market covered in this report is segmented –

1) By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach
2) By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning
3) By Drug Type: Generic, Branded
4) By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels
5) By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users

Subsegments:
1) By Nutritional Management: Dietary Modifications, Nutritional Supplements
2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations, Tablet Formulations, Powder Formulations
3) By Lifestyle Modifications Approach: Weight Management, Physical Activity Recommendations, Smoking Cessation Programs

Order your report now for swift delivery
Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Report 2025, Analysis And Outlook

Which companies dominate the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market?

Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Pfizer Inc., Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abott Laboratories, Medtronic PLC, Solvay S.A., Laboratory Corporation of America Holdings (Labcorp), Organon group of companies Metagenics LLC, Allergan PLC, Chiesi Farmaceutici S.p.A., Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, ChiRhoClin Inc., Digestive Care Inc., Alcresta Therapeutics Inc., Vivus Inc., Cilian AG, Bioserv Diagnostics Gmbh, Anthera Pharmaceuticals Inc., Aptalis Pharma Inc., First Wave BioPharma Inc., EagleBiosciences Inc., ScheBo Biotech AG.

How will evolving trends contribute to the growth of the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market?

Major companies operating in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are adopting a strategic partnership approach to enhance technology integration and expand market reach. A strategic partnership typically refers to a collaborative relationship between two or more organizations where they combine their resources, expertise, and efforts to achieve common goals or objectives. For instance, in February 2023, Codexis, Inc., a US-based protein engineering company, and Nestlé Health Science, a Switzerland-based science of nutrition, announced interim results from their Phase 1 clinical trial of CDX-7108, an investigational therapy aimed at treating exocrine pancreatic insufficiency (EPI). The results from this Phase 1 trial pave the way for further studies that could significantly improve treatment options for patients suffering from EPI.

What are the key regional dynamics of the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market, and which region leads in market share?

North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2024. The regions covered in exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Does The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Report 2025 Offer?

The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.

Exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics refer to treating a condition in which the pancreas does not produce enough digestive enzymes required for the proper breakdown and absorption of nutrients from food in the small intestine. EPI diagnostics and therapeutics play a crucial role in diagnosing and managing exocrine pancreatic insufficiency, helping individuals with EPI achieve better nutrient absorption and overall well-being.

Purchase the exclusive report now to unlock valuable market insights:
Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Report 2025, Analysis And Outlook

About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.

Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Twitter: The Business Research Company (@tbrc_info) on X
Facebook: The Business Research Company | London
YouTube: The Business Research Company
Blog: The Road Ahead for the Silicon metal size Market: Key Growth Trends and Opportunities to Watch - Latest Global Market Insights
Healthcare Blog: Latest Healthcare Research Reports - By The Business Research Company
Global Market Model: Global Market Intelligence Database